http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AT-4589-U2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac2c17e532220d91aca9a28ef60f178b
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/D21C5-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P21-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/D21C5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-06
filingDate 2000-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2001-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AT-4589-U2
titleOfInvention OXYCODON COMPOSITION WITH CONTROLLED RELEASE
abstract A method of significantly reducing the range of daily dose dosages needed to control pain in approximately 80% of patients is disclosed, comprising an oral, solid, controlled release dosage formulation comprising from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation ensures an average maximum plasma concentration of oxycodone of about 6 to about 60 ng / ml from about 2 to about 4.5 hours after administration, and from about 10 to about 14 hours after repeated "q12h" ( ie every 12 hours) administration a mean minimum plasma concentration of about 3 to about 30 ng / ml under steady-state conditions. Another embodiment relates to a method for significantly reducing the range of daily doses required to control pain in essentially all patients. Figure 5 is a graph showing the mean oxycodone plasma concentration of a 10 mg controlled release oxycodone formulation and a study reference standard made in accordance with the present invention.
priorityDate 1991-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5462328
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID1003695
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453754419
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449170443
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284371
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1003695
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6321225
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5359272
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284570
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507064
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448882717
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451008255
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8209
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284603
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID104931
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506174
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449000177
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4095
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID107665
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62223
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507804
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25137874
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5480431
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507785
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491494
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4058
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555047
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419536306
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474346
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419501369

Total number of triples: 46.